Oregon Public Employees Retirement Fund Increases Stake in Becton, Dickinson and Company (BDX)

Oregon Public Employees Retirement Fund lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 9.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,278 shares of the medical instruments supplier’s stock after acquiring an additional 2,130 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Becton, Dickinson and were worth $4,757,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. State Street Corp raised its holdings in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after purchasing an additional 342,873 shares during the period. Northern Trust Corp raised its holdings in Becton, Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after purchasing an additional 106,966 shares during the period. Finally, Fiera Capital Corp raised its holdings in Becton, Dickinson and by 7.1% in the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after purchasing an additional 183,372 shares during the period. 86.71% of the stock is owned by hedge funds and other institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $219.23 on Friday. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $225.23. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The company has a market cap of $49,889.07, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same period in the prior year, the company earned $2.12 earnings per share. The firm’s revenue was down 2.0% on a year-over-year basis. equities research analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/11/12/oregon-public-employees-retirement-fund-increases-stake-in-becton-dickinson-and-company-bdx.html.

BDX has been the topic of a number of recent analyst reports. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, July 17th. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Barclays PLC restated an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and presently has a consensus rating of “Buy” and an average target price of $213.47.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now directly owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the completion of the sale, the insider now directly owns 95,270 shares in the company, valued at $19,094,966.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,650 shares of company stock worth $12,223,970. 1.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply